The Study
Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia
This study is like writing down what happened to one kid who tried a new medicine — his weight went down and his blood sugar improved. But we don’t know if the medicine did it, or if it was because he ate better, exercised, or took other pills. It’s just one story, not proof it works for anyone else.
Analysis score
Maximum 30 for a case report.
Where the score came from
A 15-year-old boy with obesity, high blood sugar, and high uric acid got a weekly shot called Mazdutide along with his usual medicines.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 530 / 100
Quality score
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1These changes are huge for a teen — losing nearly 20 kg and fixing fatty liver and high blood sugar without side effects is very promising.
- 2He lost 16.8 kg, his blood sugar dropped from 9.6% to 7.5%, uric acid fell by 37%, triglycerides dropped 69%, LDL fell 17%, and his fatty liver disappeared.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Frontiers in Endocrinology
Year
2025
Authors
Wenfei Cheng, Zilong Chen, Puyu Li, Yingyu Zhang, Yujin Ma, Peng Liu, Hongwei Jiang
Related Content
Claims (6)
Weight loss caused by GLP-1 receptor agonists is associated with lower levels of uric acid in the blood.
In a 15-year-old adolescent with obesity, type 2 diabetes, and high uric acid, weekly injections of Mazdutide for 36 weeks along with metformin and insulin resulted in a 16.8 kg weight loss, reduced blood sugar and uric acid levels, lowered triglycerides, and resolved liver fat accumulation, with no adverse events reported.
In teenagers with obesity and type 2 diabetes, a combination of weekly Mazdutide 6 mg, metformin, and insulin for 36 weeks was linked to a 69.02% drop in triglycerides and a 17.27% drop in LDL cholesterol.
In adolescents with obesity and type 2 diabetes, a weekly injection of Mazdutide 6 mg along with metformin and insulin for 36 weeks lowered blood uric acid levels by 37%, and these lower levels stayed reduced for six weeks after stopping the treatment.
In adolescents with obesity and type 2 diabetes, treatment with weekly Mazdutide 6 mg along with metformin and insulin for 36 weeks resulted in a 21.88% decrease in HbA1c from 9.60% to 7.50%, with no hypoglycemic episodes.
In adolescents with obesity and type 2 diabetes, treatment with weekly Mazdutide 6 mg along with metformin and insulin for 36 weeks was linked to the complete disappearance of liver fat detected by ultrasound, starting at week 14 and continuing through week 36.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.